Log in to search using one of your social media accounts:

 

Drugs for Long-Term is a New Area for Ovarian Cancer Dont give up on path inhibitors too early because of toxicity
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, explains how Drugs for Long-Term is a New Area for Ovarian Cancer Dont give up on path inhibitors too early because... Author: Cancer-News Added: 04/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Rucaparib, Niraparib, and Olaparib all Show Benefit Differences between the drugs, are in their toxicities
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Rucaparib, Niraparib, and Olaparib all Show Benefit. Differences between the drugs, are in their toxiciti... Author: Cancer-News Added: 04/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 10, 2018 Category: Cancer & Oncology Source Type: podcasts

How do you indentify a toxicity being related to the axitnib or the pembrolizumab?
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers How do you indentify a toxicity being related to the axitnib or the pembrol... Author: Cancer-News Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy Can have Activity in the Brain Do better at managing toxicities
Santosh Kesari, MD, discusses how Immunotherapy Can have Activity in the Brain Do better at managing toxicities at the 2018 Oncology Summit in Huntington Beach, CA Go to: http://www.moasc.org... fo... Author: moasc Added: 03/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Is Genotype Screening Needed Before Fluoropyrimidines?
Dr David Kerr on how the recent case for DPYD screening may be on (and off) mark in addressing chemotherapy toxicity. (Source: Medscape Oncology)
Source: Medscape Oncology - March 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Immune Therapy Toxicities Related to Breast Cancer Thyroid and adrenal insufficiency
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune Therapy Toxicities Related to Breast Cancer Thyroid and adrenal insufficiency at the 2018 Oncology ... Author: moasc Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Continue to Refine Understanding of Biomarkers Find the right combinations with least toxicity
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares the Continuation to Refine Understanding of Biomarkers and Find the right combinations with least toxicity at the 2018 Oncol... Author: moasc Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 7, 2018 Category: Cancer & Oncology Source Type: podcasts

ADD - What are the options for a myeloma patient who has relapsed on a two-drug combination?
In this weeks video, Dr. Brian G.M. Durie advises that patients discuss with their doctors the many aspects of various treatments, including possible toxicities, cost issues, the patients overall he... Author: InternationalMyelomaFoundation Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
As our knowledge of immunotherapy increases, so has our understanding of its side effects. In this interview, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the types of imm... Author: VJHemOnc Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Echelon-1 Data Showed Modified Progression Free Survival Increased toxicity may not be worth a few points in overall survival
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Echelon-1 Data Showed Modified Progression Free Survival Increased toxicity may not be worth a few point... Author: moasc Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts

Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD at MOASCs... Author: moasc Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts

Gluten-Free Diets: Healthy or Potentially Toxic?
Dr David Johnson on new data suggesting that these popular diets may lead to an accumulation of heavy metals. (Source: Medscape Gastroenterology Podcast)
Source: Medscape Gastroenterology Podcast - February 6, 2018 Category: Gastroenterology Authors: Medscape Source Type: podcasts

Toxicities with IDH1 & IDH2 Inhibitors - IDH Differentiation Syndrome is a new side-effect
Deepa Jeyakumar, MD, from UC Irvine Health For Multiple Myeloma Research joins us at MOASCs Spotlight On Hematology in Huntington Beach to discuss the toxicities with IDH1 & IDH2 inhibitors and a ne... Author: moasc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2018 Category: Cancer & Oncology Source Type: podcasts

This Phase 3 Trial has Shown Improved Overall Survival - Toxicity Profile has been stable with prolonged exposure to drugs
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses this phase 3 trial has shown improved overall survival and toxicity profile has been stable with prolonged exposure to ... Author: ASHReport Added: 01/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Phase 2 Trials of BCMA Targeted Therapy - Find safety, toxicity, and efficacy in a larger patient population
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses phase 2 trials of BCMA targeted therapy and finding safety, toxicity, and efficacy in a larger patient population at the 20... Author: ASHReport Added: 01/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Who Should Get PRRT?
Soulen - Who Should Get PRRT Weighing Cumulative Toxicity Key to PRRT TreatmentMichael C. Soulen, MD of the University of Pennsylvania answers the question "Who Should Get PRRT?". He summarizes th... Author: AnnualMeetingGI2016 Added: 01/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Risks of Toxicity with Interferon - Chronic low-grade toxicities with the therapy
Ruben Mesa, MD, from UT Health San Antonio Cancer Center discusses risks of toxicity with interferon and chronic low-grade toxicities with the therapy at the 2017 American Society of Hematology. Author: ASHReport Added: 01/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Prophylactic treatment for CAR T-cell toxicity shows promising results
For CAR T-cell therapy to become mainstream, the management of related toxicities needs to be addressed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in At... Author: VJHemOnc Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Cytokine storms: CAR T-cell hyperinflammatory response distinct from cytokine release syndrome?
Cytokine release syndrome (CRS) is a relatively well-described toxicity of CAR T-cell therapy. However, their may be delayed manifestations of CRS, such as disseminated intravascular coagulation (DIC)... Author: VJHemOnc Added: 01/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 5, 2018 Category: Cancer & Oncology Source Type: podcasts

Two Reasons Osimertinib in 1st Line Good Toxicity Profile & amp; Crossing Blood Brain Barrier
Anne S. Tsao, MD of MD Anderson Cancer Center discusses two reasons Osimertinib is good for first line treatment such as it's good toxicity profile and how it crosses the blood brain barrier from the ... Author: thoraciconcology Added: 12/29/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 29, 2017 Category: Cancer & Oncology Source Type: podcasts

Osimertinib Real World Toxicity Substantially Less than 1st Gen TKIs
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Osimertinib and the real world toxicity issues including that it's substantially less than 1st generationg TKIs from the 22nd... Author: thoraciconcology Added: 12/29/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 29, 2017 Category: Cancer & Oncology Source Type: podcasts

Acute oncology: new immunotherapy guidelines
Immunotherapies can come with a range of toxicities that require the appropriate management by acute oncology services. In this interview, Liz Gifford of the University Hospital Southampton NHS Founda... Author: VJOncology Added: 12/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2017 Category: Cancer & Oncology Source Type: podcasts

The rarer toxicities of immunotherapy
Immunotherapies can induce a range of common, as well as rare, side effects. These may be difficult for healthcare professionals to spot if they have not observed them previously. In this interview, L... Author: VJOncology Added: 12/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2017 Category: Cancer & Oncology Source Type: podcasts

The systemic anti-cancer dataset (SACT): optimizing immunotherapy toxicity management
Collating data and communicating center experiences is essential to ensure that the best standard of care is provided to patients across geographical boundaries. In this interview, Liz Gifford of the ... Author: VJOncology Added: 12/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2017 Category: Cancer & Oncology Source Type: podcasts

Efficacy of first generation FLT3 inhibitors for AML
New molecules targeting specific gene mutations are showing great potential for precisely treating diseases and lowering the toxicity of treatment. In this interview, recorded at the International Con... Author: VJHemOnc Added: 12/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 7, 2017 Category: Cancer & Oncology Source Type: podcasts

The development of novel treatment modalities: regulations and expectations
Novel technologies have the potential to allow us to treat more ailments, but often come at the price of new toxicities. Speaking from the International Conference of Acute Myeloid Leukaemia 2017, Est... Author: VJHemOnc Added: 12/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 5, 2017 Category: Cancer & Oncology Source Type: podcasts

When to use bispecifics for AML
As alternatives to chemotherapy are created, the prospect of having treatments with a lower toxicity becomes more tangible. In this video, Prof. John DiPersio, MD, PhD from Washington University Schoo... Author: VJHemOnc Added: 11/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 24, 2017 Category: Cancer & Oncology Source Type: podcasts

Bispecific agents: the future of AML and MDS treatment?
It is crucial that drug toxicity is kept as low as possible to improve the quality of life of patients. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by... Author: VJHemOnc Added: 11/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 23, 2017 Category: Cancer & Oncology Source Type: podcasts

BTK inhibitors: toxicity, resistance, and combinations
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses recent developments in BTK inhibitors at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. BTK... Author: VJHemOnc Added: 11/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 21, 2017 Category: Cancer & Oncology Source Type: podcasts

Overcoming toxicities when combining PI3K inhibitors with other treatments
Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of... Author: VJHemOnc Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts

Understanding the balance between efficacy and toxicity
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the balance between efficacy and toxicity of treatments at the International Workshop on Non-Hodgkin Lym... Author: VJHemOnc Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts

A Supplement That May Block The Toxic Effects of Alcohol
Dr Lundberg shares a possible aid for metabolizing alcohol. (Source: Medscape Internal Medicine Podcast)
Source: Medscape Internal Medicine Podcast - September 26, 2017 Category: Internal Medicine Authors: Medscape Source Type: podcasts

Cisplatin with Radiation, Toxicity Problems with the Standard Regimen
Direct from ASCO 2017Highlights and New Approaches in Head and Neck Cancerhttp://cancerGRACE.org/... Author: cancergrace Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts

What to Do When a Child Has a Toxic Exposure
A free resource helps clinicians identify and manage toxic exposures in children and improve health outcomes. (Source: Medscape Medscape Podcast)
Source: Medscape Medscape Podcast - July 17, 2017 Category: General Medicine Authors: Medscape Source Type: podcasts

Unique toxicities of immunotherapy
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/S... 2017 Imedex, LLC. Author: imedex Added: 07/11/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 11, 2017 Category: Cancer & Oncology Source Type: podcasts

Research Summaries: Happiness from Ordinary and Extraordinary Experiences
Today’s research summary comes from another article in the Journal of Consumer Research. Oxygen toxicity occurs when the lungs take in a higher than normal O 2 partial pressure, which can occur in deep scuba diving. (Photo credit: Wikipedia) The big ideas: It is well established that experiential purchases (like going on a vacation) lead to greater happiness than material purchases (like buying a car). However, not much is known about which types of experiences lead to greater happiness and for whom. A dimension on which experiences reliably differ are whether they are ordinary, meaning common and frequent, or extra...
Source: The Mouse Trap - June 30, 2017 Category: Psychiatry & Psychology Authors: sandygautam Tags: happiness Research Summaries Source Type: podcasts

How and when do you begin the conversation with patients about financial toxicity?
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses how and when he beings to speak with his patients about financial toxicity at the 2017 ASCO Annual Meeting in Chicago, IL. Author: obr Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts

What interventions can alleviate financial toxicity?
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses the interventions to alleviate financial toxicity at the 2017 ASCO Annual Meeting in Chicago, IL. Author: obr Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts

What is CancerCare doing to help cancer patients with financial toxicity?
Patricia Goldsmith, CEO of CancerCare discusses the financial programs that are provided by CancerCare for cancer patients to help with treatment and cancer care costs. This was recorded at the 2017 A... Author: obr Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts

How to weigh a star —with a little help from Einstein, toxic ‘selfish genes,’ and the world’s oldest Homo sapiens fossils
This week we have stories on what body cams reveal about interactions between black drivers and U.S. police officers, the world ’s oldest Homo sapiens fossils, and how modern astronomers measured the mass of a star—thanks to an old tip from Einstein—with Online News Intern Ryan Cross. Sarah Crespi talks to Eyal Ben-David about a pair of selfish genes—one toxin and one antidote—that have been masquerading as essent ial developmental genes in a nematode worm. She asks how many more so-called “essential genes” are really just self-perpetuating freeloaders? Science Careers Editor Rac...
Source: Science Magazine Podcast - June 8, 2017 Category: Science Authors: Science Tags: Scientific Community Source Type: podcasts

SCCM Pod-VCCR5 Rumack-Matthew Nomogram and Acetaminophen Toxicity
Sean P. Kane, PharmD, BCPS, speaks with Nadia Awad, PharmD, BCPS about Rumack-Matthew nomogram and acetaminophen toxicity. In the episode, the toxidrome of acetaminophen overdose is outlined and the nuances (including clinical practice pearls) are discussed regarding the nomogram used to decide whether N-acetylcysteine is warranted for acetaminophen toxicity. (Source: SCCM PodCast - iCritical Care)
Source: SCCM PodCast - iCritical Care - May 24, 2017 Category: Intensive Care Authors: The Society of Critical Care Medicine (SCCM) Tags: Medicine Source Type: podcasts

Discussion and Concerns on Toxicity of Drugs
Jean-Pierre J. Issa, MD of Fox Chase Cancer CenterFels Institute for Cancer Research & Molecular Biology at Temple University discusses questions of concern on the the toxicity of the new epigene... Author: aacr2017 Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts

Better Drugs, New Targets and Lower Toxicity in Lung Cancer Treatment
Are there new developments in treating metastatic lung cancer? Dr. David Carbone of Ohio State University Comprehensive Cancer Center has much to report. From new medications that directly impact qual... Author: patientpower Added: 04/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 19, 2017 Category: Cancer & Oncology Source Type: podcasts

How to monitor and manage immunotherapy related events in lung cancer
Alex Spira, MD, PhD, FACP of Virginia Cancer Specialists, Fairfax, VA talks about immunotherapies and the new challenges they present for clinicians. Immunotherapy drugs lead to side effects and toxic... Author: VJOncology Added: 02/14/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 14, 2017 Category: Cancer & Oncology Source Type: podcasts

The toxicities associated with immunotherapy in lung cancer patients
Beth Eaby-Sandy MSN, CRNP, OCN, of the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA explains the different toxicities seen with immunotherapy compared to chemotherapy. Toxiciti... Author: VJOncology Added: 02/14/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 14, 2017 Category: Cancer & Oncology Source Type: podcasts

LCI Study: Treating Brain Tumors in a Less Toxic Way
Doctors from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study that was accepted for publication by the Journal of the American Medical... Author: LevineCancerInstitute Added: 02/09/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Affordability of Medication: Why Communication With Your Provider Is Essential
Financial toxicity is a big concern with cancer care today. At our recent MPN Town Meeting at City of Hope, MPN experts discuss affordability of medication and why you should be communicating with you... Author: patientpower Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts

Expanding your mind about novel psychoactives
The use of novel psychoactive substances is increasing, however there is little information about what these are, and how they work. Dr Derek Tracy, consultant psychiatrist at Oxleas NHS Foundation Trust, and David Wood, consultant physician and toxicologist at Guy's and St Thomas' NHS Foundation Trust join us to explain that doctors already... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 19, 2017 Category: Journals (General) Authors: BMJ talk medicine Source Type: podcasts

"Evolver" -- The Discovery Files
While environmental change is outpacing the rate of evolution for many other species, Atlantic killifish living in four polluted East Coast estuaries turn out to be remarkably resilient. These fish have adapted to levels of highly toxic industrial pollutants that would normally kill them. (Source: The Discovery Files)
Source: The Discovery Files - January 10, 2017 Category: Science Authors: National Science Foundation Source Type: podcasts